How should finasteride be used to treat male‑pattern androgenetic alopecia in adult men, including dosage, expected timeline for regrowth, side effects, and alternative therapies?

Finasteride for Male Androgenetic Alopecia

Prescribe finasteride 1 mg orally once daily for adult men with male-pattern baldness; expect visible improvement in 3–6 months, with optimal results at 12 months, and counsel patients that sexual side effects occur in 2–4% but typically resolve after stopping the drug. 1

Dosage and Administration

• Standard dose: finasteride 1 mg orally once daily, taken with or without food 2
• The 1 mg dose is FDA-approved specifically for androgenetic alopecia in men 2
• Treatment must be continued indefinitely; hair loss resumes approximately 2 weeks after discontinuation as DHT levels return to baseline 2

Timeline for Response

• Visible improvement generally requires 3–6 months of continuous daily therapy 1
• Optimal results are observed after 12 months of treatment 1
• Do not assess efficacy before 12 months; formal evaluation using standardized photographs should occur at this milestone 1
• Long-term data demonstrate durable improvements in scalp hair over 5 years, with progressive hair loss occurring in untreated patients 3
• Hair count increases progressively: mean improvement of 12.4 hairs/cm² at 24 weeks and 16.4 hairs/cm² at 48 weeks compared to placebo 4

Mechanism and Efficacy

• Finasteride competitively inhibits Type II 5α-reductase, reducing serum dihydrotestosterone (DHT) by approximately 70% after daily dosing 2
• Maximum DHT suppression occurs 8 hours after the first dose and is maintained throughout the 24-hour dosing interval 2
• Patient self-assessment shows improvement in 1.81 times more men than placebo in the short term and 1.71 times more in the long term; the number needed to treat is 5.6 at short term and 3.4 at long term 5
• Investigator assessment confirms improvement in 1.80 times more patients than placebo, with a number needed to treat of 3.7 5

Sexual Side Effects

• Sexual dysfunction occurs in 2–4% of men taking finasteride, including decreased libido, erectile dysfunction, reduced ejaculate volume, and rarely gynecomastia 1
• Erectile dysfunction occurs in 1–2% more patients than placebo 1
• On a 0–100 sexual function scale, finasteride produces a mean difference of 3.21 points, which is smaller than the 1.26-point decline associated with each additional year of age 1
• Sexual dysfunction tends to diminish over time with continued therapy and reverses completely after discontinuation 1
• The risk of discontinuing treatment due to sexual adverse effects is similar to placebo (relative risk 0.88) 5
• Moderate-quality evidence suggests an increased risk of erectile dysfunction (relative risk 2.22; number needed to harm 82.1) 5

PSA Monitoring

• Finasteride lowers serum PSA by approximately 50% after 12 months; clinicians must multiply the measured PSA by 2 to interpret prostate-cancer risk accurately 1, 6
• By 3 years of therapy, PSA suppression exceeds 50%, requiring a multiplier of 2.3 1, 6
• Inform the patient's primary-care physician that the patient is on finasteride so PSA values can be correctly adjusted during cancer screening 1

Combination Therapy

• Adding topical minoxidil 5% to finasteride enhances efficacy, particularly in men with moderate-to-severe hair loss 1
• Combination therapy is recommended when monotherapy provides insufficient response after 12 months 7
• Oral minoxidil 2.5–5 mg daily is an emerging off-label option that may be better tolerated than injectable platelet-rich plasma 1

Alternative Formulations

Topical Finasteride

• Topical finasteride 0.25% solution applied daily demonstrates efficacy comparable to oral finasteride 1 mg, with significantly lower systemic exposure 8
• Maximum plasma finasteride concentrations are >100 times lower with topical versus oral formulation 8
• Reduction in serum DHT is 34.5% with topical versus 55.6% with oral finasteride, reducing the likelihood of systemic sexual adverse effects 8
• Topical finasteride significantly improves target area hair count compared to placebo (adjusted mean change 20.2 vs. 6.7 hairs at week 24) 8
• Consider topical finasteride when patients are concerned about systemic side effects or prefer localized treatment 9, 8

Dutasteride

• Dutasteride 0.5 mg daily inhibits both Type I and Type II 5α-reductase and has been shown to induce better responses than finasteride, especially in the frontal area 10
• Dutasteride is not FDA-approved for androgenetic alopecia but is used off-label 10

Follow-Up Schedule

• Initial counseling should cover the 2–4% risk of sexual side effects and the rare possibility of persistent symptoms after discontinuation 1
• Reassessment at 6 months is recommended to evaluate early response 1
• Formal efficacy evaluation at 12 months using standardized photographs should follow 1

Common Pitfalls to Avoid

• Pitfall #1: Discontinuing finasteride before 12 months due to perceived lack of efficacy. Solution: Educate patients that a minimum of 12 months is required for evaluation and that early shedding may occur 1
• Pitfall #2: Failing to adjust PSA values in men undergoing prostate cancer screening. Solution: Multiply measured PSA by 2 after 12 months of therapy and by 2.3 after 3 years 1, 6
• Pitfall #3: Overstating the risk of sexual side effects, leading to nocebo effects. Solution: Provide balanced counseling that sexual dysfunction occurs in 2–4%, is typically reversible, and is smaller in magnitude than age-related decline 1, 5
• Pitfall #4: Using finasteride as monotherapy when combination with minoxidil would provide superior results. Solution: Consider adding topical minoxidil 5% in men with moderate-to-severe hair loss 1

Safety Considerations

• Finasteride is contraindicated in women of childbearing potential due to teratogenic risk to male fetuses 6
• In men, finasteride does not alter the hypothalamic-pituitary-testicular axis, cortisol, prolactin, thyroid function, or lipid profile 2
• Testosterone levels increase by approximately 10–20% but remain within the physiologic range 2
• Discontinuation due to adverse events occurs in 6–7% of patients, a rate comparable to placebo 1